iBio (IBIO) Other Non-Current Liabilities (2022 - 2023)

iBio (IBIO) posted quarterly Other Non-Current Liabilities of $263000.0 for Q3 2023, down 50.09% quarter-over-quarter from $527000.0 in Q2 2023.

iBio (IBIO) Other Non-Current Liabilities (2022 - 2023) Analysis & Trends

iBio (IBIO) has reported Other Non-Current Liabilities for 2 consecutive years, with $263000.0 the latest figure, recorded in Q3 2023.

In Q3 2023, Other Non-Current Liabilities changed N/A year-over-year to $263000.0; the TTM figure through Sep 2023 stood at $263000.0 (changed N/A YoY), while the FY2023 annual figure was $527000.0, changed N/A from the prior year.
Other Non-Current Liabilities eased to $263000.0 in Q3 2023 per IBIO's latest filing, from $527000.0 in the prior quarter.
Across five years, Other Non-Current Liabilities topped out at $1.1 million in Q4 2022 and bottomed at $263000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	iBio	172.22 Mn	172.22 Mn	-

Download Data